الفهرس 
AIM OF THE WORKOnly 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
The European Society of Cardiology Guidelines, published in 2011, recommended an endovascular-first strategy in all femoral–popliteal TASC A-C and infrapopliteal lesions, when revascularization is indicated. The low morbidity and mortality of endovascular techniques, such as percutaneous transluminal angioplasty (PTA) and stenting, make it the preferred choice of treatment in diseases such as stenosis and occlusions. Drug-eluting devices, which inhibit neointimal growth of vascular smooth muscle cells, may prevent restenosis. In recent years, drug-eluting balloons (DEBs) have emerged as an exciting technology developed to overcome the limitations of drug-eluting stents (DESs), such as stent thrombosis and dependency on prolonged dual antiplatelet therapy, and may prove efficacious in complex subsets such as small vessels and diffuse lesions, where stent results are suboptimal. In addition, DEBs have the potential for higher drug tissue bioavailability due to the higher drug surface area presented to the vessel wall compared with DESs.
Patients were Allocated to one of two groups: group A: patients were operated by Drug eluting balloons (number = 45), group B: patients were operated by standard balloons (number = 45). Study was undergone in Vascular unit, Department of General Surgery, Menoufia University Hospitals. Interventions will be performed mainly by antegrade approach and with the use of 6-French sheaths. In case of failure to recanalize, a retrograde approach is attempted. In DEBs group, pre-dilatation of the target lesion with standard balloon(s) was always performe